Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vivus stock falls as company raises $202m in predicted offering: Chelsea next?

This article was originally published in Scrip

Executive Summary

A public offering of Vivus stock predicted on Monday by Scrip saw the company raise $202.5 million to help usher its obesity drug Qnexa towards its PDUFA date with the FDA in April. The underwritten offer of 8.5 million shares at $22.50 prompted a fall in Vivus' share price of 11%, a move also predicted by Scrip.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts